Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 89-94

  Hood, S ^a,c   Birnie, D ^a   Swan, L ^a   Murray, L S ^a   Whitehouse, H ^b   Winter, P ^b   Hillis, W S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Naratriptan; Vasoconstriction and haemodynamics

Indexed keywords

NARATRIPTAN; SEROTONIN 1 AGONIST;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY; DRUG INDUCED DISEASE; FEMALE; HEADACHE; HEART HEMODYNAMICS; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; MALE; PRESSOR RESPONSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD PRESSURE; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PIPERIDINES; PULMONARY ARTERY; PULMONARY CIRCULATION; SEROTONIN AGONISTS; TIME FACTORS; TRYPTAMINES; VASOCONSTRICTION;

EID: 0033056934     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00015     Document Type: Article

References (21)

1. 1 receptor agonist. Br J Pharmacol 1993;108:260P.
2. Connor HE, O'Shaughnessy CT, Feniuk W, et al. GR85548: a potent selective agonist for the intracranial vascular 5-HT, receptor. Br J Pharmacol 1993;108:99P.
3. 1B receptors. Br J Pharmacol 1997; 120:153-9.
4. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalagia 1997; 17:145-52.
5. Fuseau E, Daille P, Kempsford RD. Absolute bioavailability of oral naratriptan: VIII Congress of the International Headache Society. Amsterdam: Meditech Media Ltd. for Glaxo Wellcome U.K., 1997.
6. The Subcutaneous Sumatriptan Derivative International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;3265:316-21.
7. Brion N, Bons J, Plas J, Bayliss EM, Advenier C. Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine. Cephalagia 1989;9(suppl 9):79-82.
8. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991;338:13-7.
9. 1 receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6.
10. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87:401-5.
11. Hood S, Birnie D, Hillis WS. The haemodynamic effects of subcutaneous sumatriptan, a 5-HT, receptor agonist. Br J Clin Pharmacol 1997;43:327-8.
12. Maassen VanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
13. Cortijo J, Marti-Cabrera M, Bernabeu E, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol 1997;122:1455-63.
14. Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989;80:1-9.
15. Chu A, Cobb FR. Vasoactive effects of serotonin in proximal coronary arteries in awake dogs. Circ Res 1987;61(suppl II):II-81-7.
16. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983;305: 627-31.
17. Connor HE, Feniuk W. Influence of the endothelium on contractile effects of 5-hydroxytryptamine and selective 5-HT agonists in canine basilar artery. Br J Pharmacol 1989;96:170-8.
18. Brum JM, Sufan Q, Lane G, Bove AA. Increased vasoconstrictor activity of proximal coronary arteries with endothelial damage in intact dogs. Circulation 1984;70:1066-73.
19. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-8.
20. Vanhoutte PM. Vascular effects of serotonin. Prog Pharmacol Clin Pharmacol 1990;7:17-25.
21. Angus JA. 5-HT receptors in the coronary circulation. Trends Pharmacol Sci 1989;10:89-90.